Development Stage
Product Candidate
Target Indication
Discovery
Pre-clinical
Phase1
Phase2
Phase3
RZ-001 
Hepatocellular carcinoma Phase1
RZ-001
- Stage : Phase I
- Indication : Hepatocellular carcinoma
- Target : Telomerase reverse transcriptase (TERT)
- Delivery Vehicle : Adenovirus
- Dose Route : Intra-tumoral injection
RZ-001_immune therapy combination
Hepatocellular carcinoma Phase1
RZ-001_immune therapy combination
- Stage : Phase I
- Indication : Hepatocellular carcinoma
- Target : Telomerase reverse transcriptase (TERT)
- Delivery Vehicle : Adenovirus
- Dose Route : Intra-tumoral injection (Adenovirus) / Intravenous (Immune checkpoint inhibitor)
Partnership
RZ-001 (GBM)
Glioblastoma Phase1
RZ-001 (GBM)
- Stage : Phase I
- Indication : Glioblastoma
- Target : Telomerase reverse transcriptase (TERT)
- Delivery Vehicle : Adenovirus
- Dose Route : Intra-tumoral injection
RZ-002
Glioblastoma Pre-clinical
RZ-002
- Stage : Pre-clinical
- Indication : Glioblastoma
- Target : Telomerase reverse transcriptase (TERT)
- Delivery Vehicle : Adenovirus
- Dose Route : Intra-tumoral injection
RZ-003
Alzheimer Discovery
RZ-003
- Stage : Discovery
- Indication : Alzheimer
- Target : Apolipoprotein E (APOE4)
- Delivery Vehicle : Adeno-associated virus (AAV)
- Dose Route : Intra-cisternal injection
RZ-004
Retinitis Pigmentosa Pre-clinical
RZ-004
- Stage : Pre-clinical
- Indication : Retinitis Pigmentosa
- Target : Mutant Rhodopsin
- Delivery Vehicle : Adeno-associated virus (AAV)
- Dose Route : Sub-retinal injection
New platform
- Discovery
New platform
- New platform
- Stage : Discovery
